Significant Ownership of Baselake Partners, LP
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Baselake Partners, LP focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ David Paolella - David Paolella, Managing Member of Baselake Management, LLC, its investment manager
- Manager location
- Troy, MI
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Baselake Partners, LP and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from Baselake Partners, LP
Significant Ownership of Baselake Partners, LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| SYBX | Synlogic, Inc. | Common Stock, par value $0.001 per share | 9.7% | $1,265,400 | 1,140,000 | Baselake Partners, LP | 20 Jan 2026 | ||
| TXMD | TherapeuticsMD, Inc. | Common Stock, par value $0.001 per share | 5.2% | $1,384,373 | 607,181 | Baselake Partners, LP | 30 Mar 2026 | ||
| NEUP | Neuphoria Therapeutics Inc. | Common Stock, $0.00001 par value per share | 4.1% | $862,110 | 222,222 | 0% | Baselake Partners, LP | 31 Dec 2025 | |
| ATHA | LeonaBio, Inc. f.k.a. Athira Pharma, Inc. | Common Stock, $0.0001 par value per share | 1.9% | $573,723 | -$921,208 | 75,789 | -62% | Baselake Partners, LP | 31 Dec 2025 |
| GBIO | Generation Bio Co. | Common Stock, $0.0001 Par Value | 0% | $0 | -$1,918,000 | 0 | -100% | Baselake Partners, LP | 09 Feb 2026 |
| KZR | Kezar Life Sciences, Inc. | Common Stock, $0.001 par value per share | 0% | $0 | 0 | Baselake Partners, LP | 11 May 2026 | ||
| KZR | Kezar Life Sciences, Inc. | Common Stock, $0.001 par value per share | 0% | 0 | -100% | Baselake Partners, LP | 11 May 2026 |
Schedules 13D/G Reported by Baselake Partners, LP:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.